Tempest Therapeutics Inc

TPST.US
Healthcare · Biotechnology
0.87
-0.06 (-6.81%)
USD · NASDAQ

Company Information

Company Name
Tempest Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US87978U1088
CIK: 0001544227
CUSIP: 87978U108
Currency: USD
Full Time Employees: 5
Phone: 415 798 8589
Fiscal Year End: December
IPO Date: Nov 12, 2012
Description:

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Address:

2000 Sierra Point Parkway, Brisbane, CA, United States, 94005

People

Directors & Officers

Name Title Year Born
Dr. Matthew Angel Ph.D. President, CEO & Director 1981
Dr. Andrew Fang Ph.D. Head of Business Development NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 24, 2026 Matthew Angel N/A Purchase 231.48K $2.16 $500.00K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Vanguard Capital Management, LLC 233.89K Mar 31, 2026 1.46% $0.00 0.00%
Vanguard Group Inc 162.56K Dec 31, 2025 1.02% $0.00 0.00%
Geode Capital Management, LLC 86.99K Mar 31, 2026 0.54% $0.00 97.20%
Vanguard Fiduciary Trust Co 68.91K Mar 31, 2026 0.43% $0.00 0.00%
BlackRock Inc 39.07K Mar 31, 2026 0.24% $0.00 0.00%
FMR Inc 33.23K Mar 31, 2026 0.21% $0.00 0.00%
Sabby Management LLC 17.86K Mar 31, 2026 0.11% $0.07 -90.00%
Northern Trust Corp 14.05K Mar 31, 2026 0.09% $0.00 0.00%
Dimensional Fund Advisors, Inc. 11.44K Mar 31, 2026 0.07% $0.00 0.00%
UBS Group AG 4.53K Mar 31, 2026 0.03% $0.00 -74.16%
Tower Research Capital LLC 2.79K Mar 31, 2026 0.02% $0.00 110.57%
Morgan Stanley - Brokerage Accounts 2.06K Mar 31, 2026 0.01% $0.00 0.00%
Advisor Group Holdings, Inc. 1.53K Mar 31, 2026 0.01% $0.00 -5.21%
Atlantic Trust Group, LLC 1.08K Dec 31, 2025 0.01% $0.00 134.78%
Federation des caisses Desjardins du Quebec 292.00 Mar 31, 2026 0.00% $0.00 0.00%
JONES FINANCIAL COMPANIES LLLP 239.00 Mar 31, 2026 0.00% $0.00 0.00%
Vanguard Global Advisers, LLC 168.00 Mar 31, 2026 0.00% $0.00 0.00%
SBI Securities Co Ltd 56.00 Mar 31, 2026 0.00% $0.00 0.00%
Royal Bank of Canada 27.00 Mar 31, 2026 0.00% $0.00 237.50%
Parallel Advisors, LLC 18.00 Mar 31, 2026 0.00% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Institutional Extnd Mkt Idx Tr 128.94K 0.87% ▲ 0.00% Jun 30, 2026
2 Vanguard Total Stock Mkt Idx Inv 104.94K 0.71% ▲ 0.00% Jun 30, 2026
3 Fidelity Extended Market Index 50.99K 0.34% ▼ 15.13% May 31, 2026
4 Abante Quant Value FI 41.82K 0.28% ▲ 0.00% May 31, 2026
5 Fidelity Series Total Market Index 15.68K 0.11% ▼ 28.31% May 31, 2026
6 Spartan Extended Market Index Pool F 12.29K 0.08% ▲ 0.00% May 31, 2026
7 NT Ext Equity Mkt Index Fund - Lending 10.94K 0.07% ▲ 0.00% Jun 30, 2026
8 Northern Trust Extended Eq Market Idx 10.94K 0.07% ▲ 141.38% Mar 31, 2026
9 NT Ext Equity Mkt Index Fund - NL 9.12K 0.06% ▲ 201.89% Jun 30, 2026
10 Fidelity Total Market Index 7.50K 0.05% ▲ 0.00% May 31, 2026

Financial Highlights

Market Cap: $14.93M
EBITDA: $-20.92M
Book Value: $0.06
Earnings/Share: $-5.71
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -61.69%
ROE (TTM): -721.00%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $20.84M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 15.98M
Shares Float: 9.73M
% Insiders: 3,178.10%
% Institutions: 2,628.70%
Short % Float: 4.25%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Gross Profit
subtotal
$0.00
SG&A
adjust
$-13.97M
R&D
adjust
$-12.61M
Operating Income
subtotal
$-26.58M
Other / Non-Operating Items
adjust
$313.00K
Net Income
subtotal
$-26.26M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about TPST.US!